Updated:
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals is a clinical-stage biotech advancing a polymer-drug delivery platform, with a lead candidate targeting knee osteoarthritis.
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals was founded in 2012 and is headquartered in Victoria, British Columbia. The company was established to commercialize a drug delivery technology that encapsulates active pharmaceutical ingredients in a biodegradable polymer microsphere, aiming to provide sustained, localized release while reducing systemic side effects. CEO James Helliwell and CSO Amanda Malone have guided the firm from preclinical work through to public-markets execution, listing on the Toronto Stock Exchange in March 2021 under the ticker EPRX. Eupraxia operates as a clinical-stage biotechnology company with a pipeline built on its DiffuSphere platform. The lead asset, EP-104IAR, is an extended-release formulation of fluticasone propionate injected directly into the knee joint for the treatment of osteoarthritis. A Phase 2b trial showed durable pain relief out to 24 weeks, with top-line data reported in 2023. A second candidate, EP-104GI, targets eosinophilic esophagitis, an inflammatory condition of the esophagus, and has completed Phase 1 studies. The company does not operate in venture-style venture capital stages; it funds R&D through public equity raises, including a US$35 million public offering in February 2024 (per company press release, February 2024). Its geographic focus is North America, with clinical sites in the United States and Canada. As a small-cap public issuer, Eupraxia maintains a lean operational structure. Professional headcount is not regularly disclosed but is consistent with a clinical-stage biotech of its market capitalization. The firm operates from Victoria, British Columbia, without additional disclosed offices. In February 2024, Eupraxia closed a US$35 million underwritten public offering to fund the Phase 3 program for EP-104IAR (per company press release, February 2024). The company has no disclosed adjacent vehicles, philanthropic foundations, or co-investment club affiliations. Eupraxia's structural differentiator lies in the DiffuSphere technology itself: a microsphere-based polymer delivery that controls drug elution over weeks to months from a single injection. Unlike many platform biotechs that out-license every asset, Eupraxia retains full ownership of its lead programs and manages its own clinical development into late-stage trials, giving it uncommon control over the commercial path for a company of its size.
General information
Firm type
other
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Victoria
Corporate office
Victoria, British Columbia, Canada
Principals
James Helliwell
Chief Executive Officer
Amanda Malone
Chief Scientific Officer
Sector focus
Frequently asked questions
What is Eupraxia's core technology platform?
Eupraxia's DiffuSphere platform uses a biodegradable polymer microsphere to encapsulate active pharmaceutical ingredients, enabling sustained, localized drug release over weeks or months from a single injection. The firm's lead candidate, EP-104IAR, applies this to deliver fluticasone propionate directly into the knee joint for osteoarthritis pain. The goal is to maximize local therapeutic effect while minimizing systemic exposure and side effects.
What stage of development is Eupraxia's lead asset in?
Lead candidate EP-104IAR completed a Phase 2b trial that demonstrated pain relief through 24 weeks in patients with knee osteoarthritis, with top-line data reported in 2023. The company is advancing the program into Phase 3. An underwritten public offering in February 2024 raised US$35 million to fund the next clinical phase.
Is Eupraxia a private company or publicly traded?
Eupraxia is publicly traded on the Toronto Stock Exchange under the ticker EPRX, having completed its IPO in March 2021. It was the first Canadian biotech to list on the TSX in over three years at the time of its public debut.
Who makes the key strategic decisions at Eupraxia?
Dr. James Helliwell serves as Chief Executive Officer and Dr. Amanda Malone as Chief Scientific Officer. Both are co-founders and have led the company from its inception in 2012 through preclinical work, Phase 2 trials, and the TSX listing. The board and management team retain full decision-making authority over pipeline prioritization and capital allocation.
Does Eupraxia have any partnerships or out-licensing deals?
As of the latest public disclosures, Eupraxia retains full ownership of its lead programs and has not announced any licensing or co-development partnerships with larger pharmaceutical companies. The company has funded its pipeline primarily through public equity raises rather than through partnership economics.
What condition does Eupraxia's second pipeline candidate target?
Eupraxia's second disclosed candidate, EP-104GI, targets eosinophilic esophagitis, a chronic inflammatory condition of the esophagus. The program has completed Phase 1 studies, applying the same DiffuSphere platform to deliver a corticosteroid locally within the esophagus.
Where are Eupraxia's clinical operations concentrated?
Eupraxia conducts its clinical trials primarily in North America, with trial sites in both the United States and Canada. The company's headquarters remain in Victoria, British Columbia, where all corporate and scientific leadership is based.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: